Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Cymer (CYMI) -- Ignore unavailable to you. Want to Upgrade?

To: jeffbas who wrote (17345)	5/4/1998 8:55:00 PM
From: puborectalis	Respond to of 25960

Jeffrey ,don't get your hopes up with this angiogenesis hype..if indeed this turned out to be somewhat effective in a small % of cancers,there would be changes in the human vasculature,I'm sure...you can't extrapolate these preliminary findings in rodents with humans.Besides Thalidomide ,unfortunately due to phocomelia effects on newborns,was removed from the market but is a great drug soon to be remarketed. This Hype is going to cause a lot of laypeople to lose their shirts.

To: jeffbas who wrote (17345)	5/4/1998 9:05:00 PM
From: Zeev Hed	Respond to of 25960

OFF TOPIC, I did not mean to start a discussion on ENMD here. And this is my last post on this subject, to quote (well, paraphrase) an official from the National Cancer Institute (on McNeil Lehrer) "... it would probably take about a year to ramp production up to have enough of the drug to begin Phase 1 clinical trials. These trials will take several more years. If everything went perfectly it may take 4-5 years for the drug to be approved for sale. ...there have been many medicines that cured mice that did not cure humans. But he is cautiously optimistic." Zeev